ALHYG Share Price

Open 0.88 Change Price %
High 0.91 1 Day 0.02 2.27
Low 0.85 1 Week 0.07 8.43
Close 0.90 1 Month 0.12 15.38
Volume 194620 1 Year -0.14 -13.46
52 Week High 1.15
52 Week Low 0.71
ALHYG Important Levels
Resistance 2 0.96
Resistance 1 0.93
Pivot 0.89
Support 1 0.87
Support 2 0.84
EPA France Most Active Stocks
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
SOI 1.38 11.29%
SOI 1.38 11.29%
SOI 1.38 11.29%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
More..
EPA France Top Gainers Stocks
ALALO 0.04 33.33%
APAM 33.78 15.72%
APAM 33.78 15.72%
ALSAS 6.29 15.62%
MLLOI 3.80 15.15%
AVQ 0.16 14.29%
DEXB 17.47 13.89%
DEXB 17.47 13.89%
MT 4.53 12.97%
MT 4.53 12.97%
More..
EPA France Top Losers Stocks
MLCAC 8.00 -21.95%
MLDEX 0.30 -18.92%
AVT 0.05 -16.67%
AVT 0.05 -16.67%
AVT 0.05 -16.67%
AVT 0.05 -16.67%
VRNL 0.51 -12.07%
EBPF 85.50 -10.00%
ALMAS 0.79 -9.20%
TONN 1.01 -8.18%
More..

Hybrigenics SA (EPA: ALHYG)

ALHYG Technical Analysis 4
As on 9th Dec 2016 ALHYG Share Price closed @ 0.90 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.88 & Strong Buy for SHORT-TERM with Stoploss of 0.82 we also expect STOCK to react on Following IMPORTANT LEVELS.
ALHYG Target for December
1st Target up-side 0.9
2nd Target up-side 0.95
3rd Target up-side 1
1st Target down-side 0.76
2nd Target down-side 0.71
3rd Target down-side 0.66
ALHYG Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.hybrigenics.com
ALHYG Address
ALHYG
3-5 impasse Reille
Paris, 75014
France
Phone: 33 1 58 10 38 00
Fax: 33 1 58 10 38 49
Interactive Technical Analysis Chart Hybrigenics SA ( ALHYG EPA France )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Hybrigenics SA
ALHYG Business Profile
Hybrigenics S.A., a bio-pharmaceutical company, focuses on the research and development of new targets and therapies against proliferative cancerous or non-cancerous diseases. Its development program is based on inecalcitol, a vitamin D receptor agonist active by oral administration, which is in clinical trial for the treatment of moderate-to-severe psoriasis, as well as planned to be tested in chronic lymphocytic leukemia patients. Oral inecalcitol is intended for the first-line treatment of metastastic castrate-resistant prostate cancer in combination with Taxotere, which is the chemotherapeutic treatment for this indication. The company has research collaboration with Servier on deubiquitinating enzymes and their inhibitors in oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes, and cardiovascular diseases. It also focuses on the research of ubiquitin-specific proteases by exploring other areas of particular relevance, such as inflammation and virology. The company, through its subsidiary, Hybrigenics Services SAS, provides Yeast Two-Hybrid (Y2H) and related services to identify, validate, and inhibit protein interactions for researchers in the areas of life sciences, using its Y2H screening platform, bioinformatics tools and database, and chemical library and chemical screening platform. Hybrigenics S.A. was founded in 1997 and is headquartered in Paris, France.